Short-Term Oral Sorafenib for Therapy of Intratumoral Shunts of Hepatocellular Carcinoma to Enable Intraarterial Treatment

CardioVascular and Interventional Radiology - Germany
doi 10.1007/s00270-019-02294-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Transcatheter Arterial Chemoembolization After Stopping Sorafenib Therapy for Advanced Hepatocellular Carcinoma

PLoS ONE
Multidisciplinary
2017English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Successful Treatment of Hepatocellular Carcinoma With Regorafenib After Sorafenib-Induced Hypersensitivity

Internal Medicine
Internal MedicineMedicine
2019English

A Case of Arteriovenous Fistula Due to a Ruptured Hepatic Aneurysm During Sorafenib Therapy for Hepatocellular Carcinoma

Acta Hepatologica Japonica
Hepatology
2017English

Triclosan Treatment Decreased the Antitumor Effect of Sorafenib on Hepatocellular Carcinoma Cells

OncoTargets and Therapy
OncologyPharmacology
2018English

Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
2015English

Addition of Local Hepatic Therapy to Sorafenib in Patients With Advanced Hepatocellular Carcinoma (Stage BCLC C)

Digestion
Gastroenterology
2014English

Can We Use Sorafenib Targeted Therapy for Advanced Hepatocellular Carcinoma (HCC) Child Pugh B

HPB
HepatologyGastroenterology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy